Vaxil Bio Ltd. (VXLLF)
- Previous Close
0.0000 - Open
0.0014 - Bid 0.0014 x --
- Ask 0.0090 x --
- Day's Range
0.0014 - 0.0014 - 52 Week Range
0.0014 - 1.7500 - Volume
3,000 - Avg. Volume
440 - Market Cap (intraday)
35.615M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0400 - Earnings Date Apr 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidate. The company was founded in 2006 and is headquartered in Toronto, Canada.
vaxil-bio.comRecent News: VXLLF
View MorePerformance Overview: VXLLF
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VXLLF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VXLLF
View MoreValuation Measures
Market Cap
712.29k
Enterprise Value
391.85k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.39
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-14.34%
Return on Equity (ttm)
-22.15%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-178k
Diluted EPS (ttm)
-0.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
448k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-432.5k